Similar Items: In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
- Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
- Evaluation of three variants of the carbapenem inactivation method for carbapenemase detection in Enterobacterales and description of the cCIM, supplemented with cloxacillin
- Carbapenem resistance in community-acquired urinary tract infections caused by Klebsiella pneumoniae and Escherichia coli in Morocco: a multicentre study (January 2022–December 2023)‘Carbapenem resistance in community UTIs in Morocco’
- Emergence of ST383 carbapenem-resistant Klebsiella pneumoniae harbouring blaNDM-5 and blaOXA-48 carbapenemase genes in a Romanian tertiary-care hospital
- Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay